Loading...
•
Dec 31, 2024
Veru Q1 2025 Earnings Report
Announced fiscal 2025 first quarter financial results and progress in clinical programs.
Key Takeaways
Veru reported a net loss of $8.9 million, or $0.06 per share, for the first quarter of fiscal 2025. The company sold its FC2 Female Condom business for $18 million and announced positive Phase 2b QUALITY study topline results for enobosarm + semaglutide.
Reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®).
The Independent Data Monitoring Committee recommended to continue the QUALITY extension study as designed.
Topline results of the Phase 2b extension maintenance study to reduce fat regain following discontinuation of GLP-1 RA are expected in the second quarter of calendar 2025.
Announced new cardiometabolic indication for sabizabulin to treat inflammation in atherosclerotic coronary artery disease.
Forward Guidance
Veru is focused on developing innovative medicines for cardiometabolic and inflammatory diseases, with key programs advancing in clinical trials and new indications being explored.
Positive Outlook
- The ongoing Phase 2b extension clinical trial will evaluate whether enobosarm can maintain muscle and prevent the fat regain that generally occurs after discontinuing a GLP-1 RA.
- The Company plans to present the full clinical efficacy and safety data set for the Phase 2b QUALITY clinical study in future scientific conferences and publications after the Phase 2b extension portion of the study is completed and unblinded.
- As the Phase 2b QUALITY study has positive topline clinical results, we plan to move forward to request an end of Phase 2 meeting with the FDA.
- The oral enobosarm modified release drug formulation will be utilized for the Phase 3 clinical studies and for commercialization.
- Veru currently has sufficient drug substance to supply the proposed Phase 2 clinical study.
Challenges Ahead
- Safety data for the Phase 2b QUALITY study remains blinded as the Phase 2b extension clinical study portion is ongoing.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...